莫西沙星和左氧氟沙星治疗老年AECOPD患者对肺功能及炎性因子水平的影响

Influence of Moxifloxacin and Levofloxacin on Lung Function and Levels of Inflammatory Factors in Elderly Patients with AECOPD

目的:探究莫西沙星和左氧氟沙星对老年慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者肺功能及炎性因子水平的影响。方法:选取本院2019年2月-2020年2月收治的94例AECOPD患者作为研究对象,采用单双数标记所有患者,奇数患者采用莫西沙星治疗(莫西沙星组),偶数患者采用左氧氟沙星治疗(左氧氟沙星组),每组47例。比较两组临床疗效、肺功能、炎性因子水平及不良反应。结果:莫西沙星组总有效治疗44例(93.62%),显著多于左氧氟沙星组的37例(78.72%),差异有统计学意义(P<0.05)。治疗后,两组第1秒用力呼气容积(FEV_1)、肺活量(FVC)水平均较治疗前明显升高,莫西沙星组FEV_1、FVC、FEV_1/FVC水平显著高于左氧氟沙星组,差异有统计学意义(P<0.05)。治疗后,两组白细胞(WBC)、C反应蛋白(CRP)、白介素-6(IL-6)水平均较治疗前明显降低,且莫西沙星组的WBC、CRP、IL-6水平显著低于左氧氟沙星组,差异有统计学意义(P<0.05)。莫西沙星组不良反应发生率为6.38%,左氧氟沙星组为14.89%,差异无统计学意义(P>0.05)。结论:采用莫西沙星治疗AECOPD可以更加有效地降低机体炎症和预后不良反应,提高患者临床疗效和肺功能。

Objective:To explore the influence of Moxifloxacin and Levofloxacin on lung function and levels of inflammatory factors in elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:From February 2019 to February 2020,94 AECOPD patients in our hospital were selected as the subjects.All patients were labeled with single and even numbers,odd patients were treated with Moxifloxacin(Moxifloxacin group),even patients were treated with Levofloxacin(Levofloxacin group),each group with 47 cases.The clinical efficacy,lung function,inflammatory factor levels and adverse reactions of the two groups were compared.Result:The total effective rate of treatment in the Moxifloxacin group was 44 cases(93.62%),which was significantly more than 37 cases(78.72%)in the Levofloxacin group,the difference was statistically significant(P<0.05).After treatment,the forced expiratory volume in one second(FEV1),forced vital capacity(FVC)levels of the two groups were significantly higher than those before treatment,and the FEV1 and FVC,FEV1/FVC levels of the Moxifloxacin group were significantly higher than those of the Levofloxacin group,the differences were statistically significant(P<0.05).After treatment,the levels of white blood cells(WBC),C-reactive protein(CRP),interleukin-6(IL-6)of the two groups were significantly lower than those before treatment,and the levels of WBC,CRP,and IL-6 of the Moxifloxacin group were significantly lower than that of the Levofloxacin group,the differences were statistically significant(P<0.05).The incidence of adverse reactions was 6.38%in the Moxifloxacin group,and 14.89%in the Levofloxacin group,and the difference was not statistically significant(P>0.05).Conclusion:The use of Moxifloxacin in the treatment of AECOPD can more effectively reduce inflammation and adverse reactions of the body,and improve the clinical efficacy and lung function of patients.